GT-30: Clinical Expansion
March 16, 2021
VGXI and Geneos Therapeutics Expand Partnership for Personalized Cancer Immunotherapies
View PDF
Investor + Media Resources
GT-30: Clinical Expansion
Geneos closes Series A1 Financing
March 3, 2021
Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs
Geneos expands its lead program for treating patients with advanced hepatocellular carcinoma
Geneos adds to its leadership team
View PDF
Upcoming Conferences
February 6, 2021
Geneos will be attending the following upcoming conferences:
- Immuno-Oncology Innovation Forum, May 2021
- AACR, April 2021
- ASCO, June 2021
GT-30: cGMP Manufacturing of First Clinical Lot
May 18, 2020
VGXI Enables Rapid GMP DNA Manufacturing Timeline for Geneos Therapeutics Personalized Cancer Immunotherapy
View PDF
Hepatocellular Carcinoma Trial
February 3, 2020
Geneos Personalized Neoantigen-Targeting Vaccine (GNOS-PV02) to be Utilized in Innovative GT-30 Hepatocellular Carcinoma Trial
View PDF
Lyfebulb-Helsinn Cancer Innovation Summit & Award
January 30, 2020
Geneos Therapeutics Named One of 11 Finalists for the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award. Niranjan Y. Sardesai, CEO of Geneos, presented at the Lyfebulb Helsinn Cancer Innovation Summit on January 30th, 2020 in Monaco.
Establish Supply Agreement
July 19, 2019
Texas Based CMO VGXI and Geneos Therapeutics Establish Supply Agreement for Production of GT- EPIC-Based Personalized Cancer Therapeutics
View PDF
Announcing First Patient Dosed
July 10, 2019
Geneos Therapeutics Announces First Patient Dosed
with its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology
View PDF